WO2004009550A1 - Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 - Google Patents

Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 Download PDF

Info

Publication number
WO2004009550A1
WO2004009550A1 PCT/IB2003/002876 IB0302876W WO2004009550A1 WO 2004009550 A1 WO2004009550 A1 WO 2004009550A1 IB 0302876 W IB0302876 W IB 0302876W WO 2004009550 A1 WO2004009550 A1 WO 2004009550A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
alkylaminocarbonyl
crc
fibrosis
Prior art date
Application number
PCT/IB2003/002876
Other languages
French (fr)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2005003200A priority Critical patent/AP2005003200A0/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to JP2004522601A priority patent/JP2005537279A/en
Priority to CA002492651A priority patent/CA2492651A1/en
Priority to EP03765230A priority patent/EP1534677A1/en
Priority to MXPA05000380A priority patent/MXPA05000380A/en
Priority to CNA038170922A priority patent/CN1668592A/en
Priority to AU2003242941A priority patent/AU2003242941A1/en
Priority to BR0312946-2A priority patent/BR0312946A/en
Priority to KR10-2005-7000849A priority patent/KR20050021497A/en
Publication of WO2004009550A1 publication Critical patent/WO2004009550A1/en
Priority to IS7614A priority patent/IS7614A/en
Priority to IL16601004A priority patent/IL166010A0/en
Priority to TNP2005000014A priority patent/TNSN05014A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to novel piperidine derivatives, methods of use and pharmaceutical compositions containing them.
  • the compounds of the invention are potent and selective inhibitors of MIP-1 (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
  • CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor.
  • MIP-1 and the related chemokines shown to interact with CCR1 (e.g..
  • RANTES (CCL5), MCP-2 (CCL8), MCP-3 (CCL7), HCC-1 (CCL14) and HCC-2 (CCL15))
  • autoimmune diseases such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g.
  • autoimmune diseases such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgi
  • pulmonary fibrosis i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis
  • fibrosis associated with end-stage renal disease fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation
  • Compounds of this invention are also potentially useful for the treatment or prevention of cancer metastasis, including but not limited to breast cancer.
  • Compounds of this invention may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
  • cytokines such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary em
  • Compounds of this invention may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria).
  • infectious agents such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), aden
  • MIP-1 and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem.. 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al.. J. Immunol..).
  • W is (C 6 -C ⁇ o)aryl or (C 2 -C 9 )heteroaryl;
  • Y is oxygen, or NR 8 wherein R 8 is hydrogen or (C C 6 )alkyl
  • Z is oxygen or NR 9 , where R 9 is hydrogen, (CrC ⁇ alkyl, or acetyl; each R 1 is independently selected from the group consisting of: hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (CrC 6 )alkyl, hydroxy or (C C 6 )alkylcarbonyloxy, (C 1 -C 6 )alkoxy;
  • R 2 , R 3 , R 4 and R 5 are each independently hydrogen or (C C 6 )alkyl optionally substituted with 1 to 3 halo groups; with the provision that at least one of R 2 , R 3 , R 4 and R 5 is (C C 6 )alkyl.
  • each R 6 is independently selected from a list consisting of: hydrogen, halo,
  • (C r C 6 )alkyl optionally substituted with 1 to 3 halo groups; cyano, (C C 6 )alkoxy, aminocarbonyl, carboxy, (C 1 -C 6 )alkylcarbonyl, or (C r C 6 )alkoxy optionally substituted by 1 to 3 halo groups; and
  • R 7 is selected from a list consisting of hydrogen, halo, (CrC 6 )alkyl optionally substituted with 1 to 3 halo groups, [(C 1 -C 6 )alkyl] 2 amino(C 1 -C 6 )alkylaminocarbonyl, amino(CrC 6 )alkylaminocarbonyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylaminocarbonyl cyano, (C C 6 )alkoxy, aminocarbonyl, (C r C 6 )alkylaminocarbonyl, [(d- C 6 )alkyl] 2 aminocarbonyl, , (C C 6 )alkylsulfonylamino, (C
  • C 9 heterocyclecarbonyl, aminocarbonyl(C 2 -C 9 )heterocyclecarbonyl, carboxy(C 2 - Cg)heterocyclecarbonyl, amino(C 2 -C 9 )heteroaryl(C 1 -C 6 )alkyl, (CrC 6 )alkylamino(C 2 - Cg)heteroaryl(C ⁇ -C 6 )alkyl, [(C 1 -C 6 )alkyl] 2 amino(C 2 -C 9 )heteroaryl(C 1 -C 6 )alkyl, (C 2 - C 9 )heteroarylamino(CrC 6 )alkyl, (C 2 -C 9 )heteroarylaminocarbonyl(C 1 -C 6 )alkoxy, (C r C 6 )alkylsulfonylaminocarbonyl(C C 6 )alkoxy, aminocarbonyl(C
  • Preferred compounds of the formula I include those wherein R 1 is halo and a is 1 or 2.
  • Preferred compounds of the formula I include those wherein Y is oxygen.
  • Preferred compounds of the formula I include those wherein Z is oxygen.
  • Preferred compounds of the formula I include those wherein Z is NH.
  • Preferred compounds of the formula I include those wherein W is phenyl.
  • Preferred compounds of the formula I include those wherein W is pyridyl.
  • Preferred compounds of the formula I include those wherein b is 0, 1 or 2, and R 6 is selected from a list consisting of halo, (C C 6 )alkyl, cyano, or (C 6 )alkylcarbonyl.
  • Preferred compounds of the formula I include those wherein c is 0, and R 7 is selected from a list consisting of aminocarbonyl, (C C 6 )alkylsulfonylamino, (C C 6 )alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(C 1 -C 6 )alkylaminocarbonyl, (C
  • Preferred compounds of the formula I include those wherein c is 1 , and R 7 is selected from a list consisting of (CrC 6 )alkylsulfonylaminocarbonyl(CrC 6 )alkoxy, (C 2 - C 9 )heteroarylaminocarbonyl(C C 6 )alkoxy, (CrC 6 )alkylsulfonylaminocarbonyl, aminocarbonyl, or carboxy.
  • Preferred compounds of the formula I include those wherein R 2 and R 3 are both methyl groups and R 4 and R 5 are both hydrogen.
  • Preferred compounds of the formula I include those wherein R 2 and R 3 are trans and Yand R 3 are trans; having relative stereochemistry as shown below.
  • Preferred compounds of the formula I include those wherein R 1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen; R 2 and R 3 are methyl; R 4 and R 5 are hydrogen; R 2 and R 3 are trans; Y and R 3 are trans; W is phenyl; b is 0, 1 or 2; R 6 is selected from the group consisting of halo, (C ⁇ -C 6 )alkyl, cyano, or (C 1 -C 6 )alkylcarbonyl; c is 0; and R 7 is selected from the group consisting of: aminocarbonyl, (CrC- 6 )alkylsulfonylamino, (C r C 6 )alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(d- C 6 )alkylaminocarbonyl, (C C 6 )alkylaminocarbonyl, hydroxy(C
  • Preferred compounds of the formula I include those wherein R 1 halo; a is 1 or 2; Y is oxygen; Z is oxygen or NH, R 2 and R 3 are methyl; R 4 and R 5 are hydrogen; R 2 and R 3 are trans; Y and R 3 are trans; W is pyridyl; b is 0, 1 or 2; R 6 is selected from the group consisting of halo, (CrC 6 )alkyl, cyano, or (CrC 6 )alkylcarbonyl; c is 0; and R 7 is selected from the group consisting of: aminocarbonyl, (C r C 6 )alkylsulfonylamino, (C ⁇ -C 6 )alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(C ⁇ -C 6 )alkylaminocarbonyl, (C r C 6 )alkylaminocarbonyl, hydroxy(C C 6 )alkylcarbonylamino, amino
  • Preferred compounds of the formula I include those wherein R 1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen; R 2 and R 3 are methyl; R 4 and R 5 are hydrogen; R 2 and R 3 are trans; Y and R 3 are trans; W is phenyl; b is 0, 1 or 2; R 6 is selected from the group consisting of: halo, (C C 6 )alkyl, cyano, or (C r C 6 )alkylcarbonyl; c is 1 ; and R 7 is selected from the group consisting of: (C r C 6 )alkylsulfonylaminocarbonyl(C C 6 )alkoxy, (C 2 -C 9 )heteroarylaminocarbonyl(C 1 - C 6 )alkoxy, (C ⁇ -C 6 )alkylsulfonylaminocarbonyl, aminocarbonyl, aminosulfonyl, or carboxy.
  • Preferred compounds of the formula I include those wherein R halo; a is 1 or 2; Y is oxygen; Z is oxygen or NH, R 2 and R 3 are methyl; R 4 and R 5 are hydrogen; R 2 and R 3 are trans; Yand R 3 are trans; W is pyridyl; b is 0, 1 or 2; R 6 is selected from the group consisting of: halo, (C C 6 )alkyl, cyano, or (C C 6 )alkylcarbonyl; c is 1 ; and R 7 is selected from the group consisting of: (C 1 -C 6 )alkylsulfonylaminocarbonyl(C C 6 )alkoxy, (C 2 -C 9 )heteroarylaminocarbonyl(C 1 -C 6 )alkoxy, (C r C 6 )alkylsulfonylaminocarbonyl, aminocarbonyl, aminosulfonyl or carboxy.
  • the most preferred compounds of the formula I are those selected from the group consisting of: 2-(4-Chloro-phenoxy)-1 -(4-phenoxy-piperidin-1 -yl)-ethanone; 2-(4-Chloro-phenoxy)-1-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-ethanone; 5-Chloro-2- ⁇ 2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy ⁇ -benzamide; (5-Chloro-2- ⁇ 2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy ⁇ -phenyl)- urea;5-Chloro-2- ⁇ (2,4-c/ ' s)-(2,5-frans)- 2-[4-(4-fluoro-phenoxy)-2,5-dimethyl-piperidin-
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e.
  • idiopathic pulmonary fibrosis interstitial pulmonary fibrosis
  • fibrosis associated with end-stage renal disease fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or
  • This invention also relates to a pharmaceutical composition for treating or preventing cancer metastasis, including but not limited to breast cancer.
  • This invention also relates to a pharmaceutical composition for preventing production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
  • cytokines such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary
  • This invention also relates to a pharmaceutical composition for preventing tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria).
  • infectious agents such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • disorders and conditions are those enumerated in the preceding paragraph.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e.
  • idiopathic pulmonary fibrosis interstitial pulmonary fibrosis
  • fibrosis associated with end-stage renal disease fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or
  • the present invention also relates to a method for treating or preventing cancer metastasis, including but not limited to breast cancer.
  • the present invention also relates to a method for preventing the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL- 6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
  • cytokines such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure,
  • the present invention also relates to a method for preventing tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria).
  • infectious agents such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV
  • the present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e.
  • idiopathic pulmonary fibrosis interstitial pulmonary fibrosis
  • fibrosis associated with end-stage renal disease fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or
  • compositions of this invention are also potentially useful for the treatment or prevention of cancer metastasis, including but not limited to breast cancer.
  • Pharmaceutical compositions of this invention may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
  • cytokines such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphy
  • compositions of this invention may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H.
  • infectious agents such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H.
  • pylori infection inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria) in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex fungal meningitis, lyme disease, malaria
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes
  • autoimmune diseases such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes
  • fibrosis e.g. pulmonary fibrosis (i.e.
  • idiopathic pulmonary fibrosis interstitial pulmonary fibrosis
  • fibrosis associated with end-stage renal disease fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory, .Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; ' vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy
  • reaction 1 of Preparation A the compound of formula II is converted to the corresponding compound of formula IV by treating II with a compound of formula III in the presence of a base, such as sodium methoxide and heat.
  • a base such as sodium methoxide and heat.
  • reaction 2 of Preparation A the compound of formula IV is cony ⁇ rted to the corresponding compound of formula V by reacting with carbonic acid di-tert- butyl ester in the presence of a base, such as sodium hydroxide, at ambient temperature for a time period between 5 hours and 15 hours, preferably around 12 hours.
  • a base such as sodium hydroxide
  • reaction 1 of Preparation B the compound of formula V, which is either commercially available or has been prepared according to Preparations A, is converted to the corresponding compound of formula VI by reacting with a reducing agent, such as L-selectride, in an aprotic solvent, such as tetrahydrofuran, to give a diastereomeric mixture of alcohols, which are separated at this stage by silica gel chromatography.
  • a reducing agent such as L-selectride
  • aprotic solvent such as tetrahydrofuran
  • Y is NH and a is 1 , 2, 3, 4, or 5, in the presence of a reducing agent, such as sodium cyanoborohydride, in the presence of a polar aprotic solvent, such as dichloroethane.
  • a reducing agent such as sodium cyanoborohydride
  • a polar aprotic solvent such as dichloroethane
  • reaction 1 of the Preparation C the compound of formula VIII is converted to the corresponding compound of formula IX by reacting VIII with an appropriate amine of the formula, HNR 8 R 9 , wherein R 8 and R 9 are each independently selected from a group, including but not limited to, hydrogen, a nitrogen containing (C 2 - C 9 )heterocycloalkyl or (C 2 -C 9 )heteroaryl group, or an optionally substituted (C C 6 )alkyl, or R 18 and R 19 are taken together with the nitrogen to which they are attached to form (C 2 -Cg)heterocycloalkyl or (C 2 -Cg)heteroaryl group, in the presence of a polar aprotic solvent, such as methylene chloride.
  • the reaction mixture is stirred, at ambient temperature, for a time period between about 1 hour to about 24 hours, preferably about 12 hours.
  • reaction 2 of Preparation C the compound of formula IX is converted to the corresponding compound of formula X by reacting IX with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide.
  • a base such as sodium hydride
  • a polar aprotic solvent such as dimethylformamide
  • reaction 3 of Preparation C the compound of formula VIII is converted to the corresponding compound of formula XI by reacting VIII with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile.
  • the reaction is stirred, at ambient temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours.
  • R 8 and R 9 are each independently selected from a group, including but not limited to, hydrogen, a nitrogen containing (C 2 -Cg)heterocycloalkyl or (C 2 - C 9 )heteroaryl group, or an optionally substituted (C C 6 )alkyl, or R 18 and R 19 are taken together with the nitrogen to which they are attached to form (C 2 -C 9 )heterocycloalkyl or (C 2 -C 9 )heteroaryl group, is then added and the reaction mixture so formed is stirred, at ambient temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
  • reaction 4 of Preparation C the compound of formula XI is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Preparation C.
  • reaction 1 of Preparation D the compound of formula XIII is converted to the corresponding compound of the formula XIV by treating with a reducing agent, such as lithium aluminum hydride, in an aprotic solvent, such as tetrahydrofuran.
  • a reducing agent such as lithium aluminum hydride
  • an aprotic solvent such as tetrahydrofuran.
  • the reaction mixture is heated to reflux for a time period between 1 hour and 6 hours, preferably about 2 hours.
  • reaction 2 of Preparation D the compound of formula XIV is converted to the corresponding compound of the formula XV by first treating with an activating agent such as sulfonyl chloride, in the presence of an aprotic solvent, ' such as chloroform.
  • an activating agent such as sulfonyl chloride
  • an aprotic solvent such as chloroform
  • the reaction is heated to reflux, for a time period between about 1 hour to about 10 hours, preferably about 3 hours.
  • the resulting alkyl chloride is then treated with a cyanide source, such as potassium cyanide, in the presence of an aprotic solvent, such as acetonitrile.
  • the reaction mixture is stirred at ambient temperature for a time period between about 1 hour to about 10 hours, preferably about 3 hours.
  • reaction 3 of Preparation D the compound of formula XV is converted to the compound of formula XVI, wherein j is 1, by first treating XV with base, such as potassium hydroxide in water.
  • base such as potassium hydroxide in water.
  • the reaction mixture is heated to reflux for a time period between about 1 hour to about 10 hours, preferably about 6 hours.
  • the resulting carboxylic acid is treated with acid, such as 47% aqueous hydrogen bromide to produce the deprotected phenol.
  • the reaction mixture is heated to reflux for a time period between about 10 hours to about 30 hours, preferably about 24 hours.
  • the deprotected phenol is finally converted to the corresponding compound of formula XVI, wherein j is 1, by refluxing in ethanol in the presence of an acid, such as sulfuric acid, for a time period between about 8 hours to about 16 hours, preferably about 12 hours.
  • an acid such as sulfuric acid
  • reaction 4 of Preparation D the compound of formula XIII is converted to the corresponding compound of formula XVI, wherein j is 2 or 3, by first treating the ester with a reducing agent, such as diisobutylaluminum hydride, in the presence of an aprotic solvent, such as toluene.
  • a reducing agent such as diisobutylaluminum hydride
  • an aprotic solvent such as toluene.
  • the resulting aldehyde is treated with a phosphonium ylide derived from the phosphonium salt of the formula
  • g is 1 or 2 in the presence of an aprotic solvent, such as tetrahydrofuran.
  • an aprotic solvent such as tetrahydrofuran.
  • the reaction is refluxed for a time period between about 4 hours to about 16 hours, preferably about 10 hours.
  • the resulting olefin is then reduced by shaking under a positive pressure of hydrogen in the presence of a catalyst, such as 20% palladium hydroxide on carbon, in the presence of a protic solvent such as ethanol.
  • a catalyst such as 20% palladium hydroxide on carbon
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride.
  • Z is oxygen, which is either commercially available or is prepared according to Preparations D and E, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone.
  • the reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
  • reaction 1 of Scheme 2 the compound of formula VII is converted to the corresponding compound of formula I by reacting VII with a compound of the formula
  • A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride.
  • a polar aprotic solvent such as methylene chloride.
  • reaction 2 of Scheme 3 the compound of formula XVIII wherein Z is oxygen, or NH, is converted to the corresponding compound of formula I where W is a (C 2 -C 9 )heteroaryl group, by reacting with a compound of formula Hal-W, wherein Hal is a chloro or bromo and W is an appropriately functionalized heteroaryl group, in the presence of a base, such as sodium hydride, in an aprotic solvent, such as tetrahydrofuran.
  • reaction 1 of Scheme 4 the compound of formula XVII is converted to the corresponding compound of formula XIX according to the procedure described above in reaction 2 of Scheme 1.
  • reaction 2 of Scheme 4 the compound of formula XIX is converted to the corresponding compound of formula XX by reacting XIX with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at ambient temperature.
  • reaction 3 of Scheme 4 the compound of formula XX is converted to the corresponding amide or acylsulfonamide of formula I, by reacting XX with an appropriate amine or sulfonamide in the presence of 4-dimethylaminopyridine, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. The resulting reaction mixture is stirred overnight at ambient temperature.
  • reaction 1 of Scheme 5 the compound of formula XVII is converted to the corresponding compound of formula XXI according to the procedure described above in reaction 2 of Scheme 1
  • reaction 2 of Scheme 5 the compound of formula XXI is converted to the corresponding compound of formula XXII by hydrogenating XXI in the presence of a catalyst, such as platinum on carbon, and a polar protic solvent, such as ethanol.
  • a catalyst such as platinum on carbon
  • a polar protic solvent such as ethanol.
  • the reaction is carried out under a positive pressure of hydrogen gas between about 30 psi to about 40 psi, preferably about 35 psi, for a time period between about 15 minutes to about 1 hour, preferably 30 minutes.
  • the compound of formula XXII is converted to the corresponding urea of formula I, by first reacting XXII with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an appropriate amine.
  • a base such as pyridine
  • a polar aprotic solvent such as methlyene chloride
  • cyanoguanidines of the formula I the compound of formula XXII is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate. The resulting reaction mixture is heated to reflux overnight. The N-cyano-S-methyl- isothiourea intermediate is then reacted with an appropriate amine in the presence of a polar protic solvent, such as methanol, to form the cyanoguanidine of formula I.
  • an aprotic solvent such as tetrahydrofuran
  • the compound of formula XXII is reacted with an appropriate acid in the presence of N-methylmorpholine, O-benzotriazole-1- yl-N,N,N ,N -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride, to form the amide of formula I.
  • a polar aprotic solvent such as methylene chloride
  • the compound of formula XXII is reacted with an appropriate aldehyde in the presence of a reducing agent, such as sodium triacetoxyborohydride, in the presence of a polar solvent, such as methanol.
  • a reducing agent such as sodium triacetoxyborohydride
  • reaction 2 of Scheme 6 the compound of formula XXIII is converted to the corresponding compound of formula I by reacting XXIII with an appropriate amine in the presence of a 10:1 ratio solution of dichloroethane/acetic acid.
  • the reaction mixture is stirred, at ambient temperature, for a time period between about 30 minutes to about 2 hours, preferably about 1 hour.
  • a reducing agent such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at ambient temperature. If the amine thus formed is secondary, the compound of formula I may further be reacted according to the procedure described above in reaction 3 of Scheme 5, to provide ureas, sulfonamides, cyanoguanidines, or amides.
  • the acid compound of formula XX is conyerted to the corresponding compound of formula XXIV by treating XX with thionyl chloride neat or in an aprotic solvent, at ambient temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour.
  • the acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H 3 CO)(H 3 C)NH » HCI, in the presence of an amine base, such as triethylamine.
  • the reaction mixture is stirred, at ambient temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
  • the amide compound of formula XXIV is converted to the corresponding compound of formula I by reacting XXIV with a (C 2 -C 9 )heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about -100°C to ambient temperature, preferably about -78°C.
  • the resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hours, preferably about 12 hours, at a temperature between about -78°C to about 50°'C, preferably about 20°C.
  • reaction 1 of Scheme 8 the compound of formula XVII is converted to the corresponding compound of formula XXV, wherein j is 1 , 2, or 3, according to the procedure described above in reaction 2 of Scheme 1..
  • reaction 2 of Scheme 8 the compound of formula XXV, wherein j is 1 , 2, or 3, is converted to the corresponding compound of formula XXVI, wherein j is 1 , 2, or 3, according to the procedure described above in reaction 2 of Scheme 4.
  • reaction 3 of Scheme 8 the compound of formula XXVI, wherein j is 1 , 2, or
  • reaction 1 of Scheme 9 the compound of formula XXV, wherein j is 0, 1 , 2, or 3, is converted to the corresponding compound of formula XXVII wherein j is 0, 1 , 2, or 3, by reacting with a reducing agent, such as sodium borohydride, in a protic solvent, such as tert-butyl alcohol.
  • a reducing agent such as sodium borohydride
  • a protic solvent such as tert-butyl alcohol.
  • reaction 2 of Scheme 9 the compound of formula XXVII, wherein j is 0, 1, 2, or 3, is converted to the corresponding compound of formula I by first treating with thionyl chloride, in the presence of an aprotic solvent, such as chloroform. The reaction is heated to reflux, for a time period between about 1 hour to about 10 hours, preferably about 3 hours.
  • the resulting alkyl chloride is then treated with sodium sulfite in a polar protic solvent, such as ethanol and water, and heated to a temperature between 90°C and 150°C, preferably around 110°C, for a time period between 10 and 20 hours, preferably 12 hours.
  • a polar protic solvent such as ethanol and water
  • the resulting sulfonate is treated with phosphorous pentachloride in an aprotic solvent, such as toluene, at a temperature between ambient and reflux, preferably at reflux for a time period between 1 hour and 8 hours, preferably 3 hours to give the corresponding sulfonyl chloride.
  • the sulfonyl chloride is then reacted with an appropriate amine in a polar aprotic solvent, such as tetrahydrofuran, at ambient temperature for a time period between 3 hours and 24 hours, preferably 12 hours.
  • a polar aprotic solvent such as tetrahydrofuran
  • the sulfonamide can be taken on further to acylsulfonamides of the formula I by treating with an acid chloride in the presence of base, such as triethylamine, in a aprotic solvent, such as dichloromethane, at ambient temperature.
  • the pressure of each of the above reactions is not critical. Generally, the reactions are conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
  • the compounds of the formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the basic compounds of this invention are readily prepared by treating the basic compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, a solid salt is obtained.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [La, 1 ,1 '-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
  • pharmacologically acceptable anions such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitart
  • Those compounds of the formula I that are also acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non- toxic base salts with the herein described acidic compounds of formula I. These non- toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
  • the present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium.
  • the alkyl groups referred to herein may be linear or branched, and they may also be cyclic (e.g.. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) or bicyclic (e.g., norbomanyl, bicyclo [3.2.1]octane) or contain cyclic groups.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • Heterocyclyl- when used herein refers to, but is not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1 ,3- oxazolidin-3-yl, isothiazolidinyl, 1 ,3-thiazolidin-3-yl, 1 ,2-pyrazolidin-2-yl, 1 ,3- pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1 ,2-tetrahydrothiazin-2-yl, 1 ,3- tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-t
  • (C 2 - C 9 )heterocyclyl ring is attached through a carbon or a nitrogen atom.
  • (C 2 -C 9 )Heteroaryl when used herein refers to, but is not limited to, furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1 ,3,5-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,5- thiadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1 ,2,3-triazinyl
  • compositions containing and methods of treating or preventing comprising administering prodrugs of compounds of the formula I.
  • Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
  • Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I.
  • the amino acid residues include the 20 naturally occurring ar ⁇ ipo acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
  • Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain.
  • This invention also provides for introduction of hydrogen isotopes (i.e., deuterium, tritium) by replacing 1 H 2 with 2 H 2 or 3 H 2 in the above procedure.
  • the compounds of this invention include all conformational isomers (e.g.. cis and trans isomers.
  • the compounds of the present invention have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms.
  • This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them. In this regard, the invention includes both the E and Z configurations.
  • the compounds of formula I may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
  • the active compounds are potent inhibitors of MIP-1 ⁇ (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
  • CCR1 CCR1 receptor
  • the CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor.
  • RANTES (CCL5), MCP-2 (CCL8), MCP-3 (CCL7), HCC-1 (CCL14) and HCC-2 (CCL15))
  • autoimmune diseases such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, juvenile arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, neuroimmunologic disease (multiple sclerosis (MS) primary progressive MS, secondary progressive MS, chronic progressive MS, progressive relapsing MS, relapsing remitting MS, worsening MS), polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (such as pulmonary fibrosis (for example
  • This method of treatment may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
  • cytokines such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith.
  • This method of treatment may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-
  • infectious agents such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-
  • CMV cytomegalovirus
  • adenoviruses Herpes viruses (Herpes zoster and,, Herpes simplex) fungal meningitis, lyme disease, malaria).
  • the activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E.,
  • MIP-1 Proprotech, Inc., P.O. Box 275, Rocky Hill NJ
  • test agonists tissue culture medium supplemented with 1 mg/ml of bovine serum albumin.
  • MIP-1 Proprotech, Inc., P.O. Box 275, Rocky Hill NJ
  • a polycarbonate filter is then applied and the upper chamber fastened.
  • the amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1 should be adequate).
  • THP-1 cells ATCC TIB-202
  • primary human monocytes or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound.
  • Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.
  • THP-1 cells 90 minutes for primary monocytes
  • the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
  • the chamber (a 96 well variety manufactured by
  • Neuroprobe can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.
  • the filter For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.
  • Dif Quik® dye American Scientific Products
  • the number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound).
  • the quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used.
  • the 50% inhibition point is then determined using a line fit analysis for all concentrations tested.
  • the line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a valid assay.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
  • the active compounds of the invention may also be formulated for sustained delivery.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g.. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g.. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g.. sodium lauryl sulphate).
  • binding agents e.g.... pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g.. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters or ethyl alcohol
  • the composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, ⁇ g ⁇ , in ampules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • Aerosol formulations for treatment of the conditions referred to above are preferably arranged so that each metered dose or "puff' of aerosol contains 20 ⁇ g to 1000 ⁇ g of the compound of the invention.
  • the overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg.
  • Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time.
  • the active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626,
  • the compounds of the invention may also be utilized in combination therapy with other therapeutic agents such as those that inhibit immune cell activation and/or cytokine secretion or action (i.e. Cyclosporin A, ISAtx247, Rapamycin, Everolimus, FK-506, Azathioprine, Mycophenolate mofetil, Mycophenolic acid, Daclizumab, Basiliximab, Muromonab, Horse anti-thymocyte globulin, Polyclonal rabbit antithymocyte globulin, Leflunomide, FK-778 (MNA-715), FTY-720, BMS- 188667 (CTLA4-lg), BMS-224818 (CTLA4-lg), RG-1046 (CTLA4-lg), Prednisone, Prednisolone, Methylprednisolone suleptanate, Cortisone, Hydrocortisone, Methotrexate, Sulfasalazine, Etanercept,
  • Example 2-4 The title compounds for Example 2-4 were prepared by a method analogous to that described in Example 1.
  • Example 6-10 were prepared by a method analogous to that described in Example 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of the formula (I) wherein a, b, c R1, R2, R3, R4, R5, R6, R7, Q, W, Y, and Z are defined as above , useful as potent and selective inhibitors of MIP-1α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).

Description

PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-IALPHA BINDING TO ITS RECEPTOR CCRl
NOVEL PIPERIDINE DERIVATIVES This application claims the benefit of priority of United States provisional Patent Application Serial No. 60/397,108 filed July 18, 2002, which is incorporated herein in its entirety for all purposes. Background of the Invention
The present invention relates to novel piperidine derivatives, methods of use and pharmaceutical compositions containing them.
The compounds of the invention are potent and selective inhibitors of MIP-1 (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor. These compounds also inhibit MIP- 1 (and the related chemokines shown to interact with CCR1 (e.g.. RANTES (CCL5), MCP-2 (CCL8), MCP-3 (CCL7), HCC-1 (CCL14) and HCC-2 (CCL15))) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; and sequelae associated with certain cancers such as multiple myeloma. Compounds of this invention are also potentially useful for the treatment or prevention of cancer metastasis, including but not limited to breast cancer. Compounds of this invention may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith). Compounds of this invention may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria). MIP-1 and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem.. 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al.. J. Immunol.. 1806-1812 (1996), and Kuna et al.. J. Allergy Clin. Immunol. 321 (1994)). Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1 or gene disruption have provided direct evidence for the role of MIP-1 α and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith et al., J. Immunol. 153. 4704 (1994) and Cook et al.. Science, 269, 1583 (1995)). Together this data demonstrates that CCR1 receptor antagonists would potentially be an effective treatment of several immune based diseases. The compounds described within are potent and selective antagonists of the CCR1 receptor.
Summary of the Invention The present invention relates to a compound of the formula
Figure imgf000004_0001
or pharmaceutically acceptable salts, tautomers, and pro-drugs thereof; wherein a is 1 , 2, 3, 4 or 5; b is O, 1 , 2, 3, or 4; c is 0 or 1 ; Q is (C C6)alkyl;
W is (C6-Cιo)aryl or (C2-C9)heteroaryl;
Y is oxygen, or NR8 wherein R8 is hydrogen or (C C6)alkyl;
Z is oxygen or NR9, where R9 is hydrogen, (CrC^alkyl, or acetyl; each R1 is independently selected from the group consisting of: hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (CrC6)alkyl, hydroxy or (C C6)alkylcarbonyloxy, (C1-C6)alkoxy;
R2 , R3, R4 and R5 are each independently hydrogen or (C C6)alkyl optionally substituted with 1 to 3 halo groups; with the provision that at least one of R2 , R3, R4 and R5 is (C C6)alkyl. each R6 is independently selected from a list consisting of: hydrogen, halo,
(CrC6)alkyl optionally substituted with 1 to 3 halo groups; cyano, (C C6)alkoxy, aminocarbonyl, carboxy, (C1-C6)alkylcarbonyl, or (CrC6)alkoxy optionally substituted by 1 to 3 halo groups; and
R7 is selected from a list consisting of hydrogen, halo, (CrC6)alkyl optionally substituted with 1 to 3 halo groups, [(C1-C6)alkyl]2amino(C1-C6)alkylaminocarbonyl, amino(CrC6)alkylaminocarbonyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonyl cyano, (C C6)alkoxy, aminocarbonyl, (CrC6)alkylaminocarbonyl, [(d- C6)alkyl]2aminocarbonyl, , (C C6)alkylsulfonylamino, (C
C6)alkylsulfonylaminocarbonyl, ureido, aminosulfonyl, [(Cι-C6)alkyl]2aminosulfonyl, (C C6)alkylaminosulfonyl, [(CrC6)alkyl]2aminocarbonyl(CrC6)alkylaminocarbonyl, (C1-C6)alkylaminocarbonyl(CrC6)alkylaminocarbonyl, aminocarbonyl(Cr
C6)alkylaminocarbonyl, (CrC6)alkylsulfonylamino, hydroxy(C
C6)alkylcarbonylamino, ureido(C C6)alkylaminocarbonyl, [(C1-C6)alkyl]2urιeido(Cr C6)alkylaminocarbonyl, (CrC6)alkylureido(CrC6)alkylaminocarbonyl, ' (C2-
Cg)heteroarylaminocarbonyl, carboxy, (C1-C6)alkoxy(C1-C6)alkyl(C2-
Cg)heterocyclecarbonyl, (C2-C9)heterocyclecarbonyl, hydroxy(C2-
C9)heterocyclecarbonyl, aminocarbonyl(C2-C9)heterocyclecarbonyl, carboxy(C2- Cg)heterocyclecarbonyl, amino(C2-C9)heteroaryl(C1-C6)alkyl, (CrC6)alkylamino(C2- Cg)heteroaryl(Cι-C6)alkyl, [(C1-C6)alkyl]2amino(C2-C9)heteroaryl(C1-C6)alkyl, (C2- C9)heteroarylamino(CrC6)alkyl, (C2-C9)heteroarylaminocarbonyl(C1-C6)alkoxy, (Cr C6)alkylsulfonylaminocarbonyl(C C6)alkoxy, aminocarbonyl(C C6)alkoxy, carboxy(CrC6)alkoxy, aminosulfonyl, (C C6)alkylcarbonylaminosulfonyl, hydroxy(CrC6)alkylcarbonylaminosulfonyl, (Cι-C6)alkoxycarbonylaminosulfonyl, (C1-C6)alkoxy(C1-C6)alkylcarbonylaminosulfonyl, hydroxysulfonyl,, hydroxy, hydroxy(C1-C6)alkylaminocarbonyl, carboxy(C2-C9)heterocycloxy or
[carboxy][amino](C C6)alkoxy, aminocarbonyl(C C6)alkylcarbonylamino, ' (C C6)alkylaminocarbonyl(CrC6)alkylcarbonylamino, [(Cι-C6)alkyl]2aminocarbonyl(Cr C6)alkylcarbonylamino, amino(CrC6)alkylcarbonylamino, (C1-C6)alkylamino(C1- C6)alkylcarbonylamino, [(CrC6)alkyl]2amino(C1-C6)alkylcarbonylamino, ureido(C C6)alkylcarbonylamino, (C1-C6)alkylureido(C -C6)alkylcarbonylamino, [(C
C6)alkyl]2ureido(CrC6)alkylcarbonylamino, amino(CrC6)alkylsulfonylamino, amino(CrC6)alkylcarbonylaminosulfonyl, (C C6)alkylamino(Cr
C6)alkylcarbonylaminosulfonyl, . [(C C6)alkyl]2amino(C1- C6)alkylcarbonylaminosulfonyl, aminosulfonylamino, (C
C6)alkylaminosulfonylamino, [(C1-C6)alkyl]2aminosulfonylamino, (C2-
Cg)heterocycloxy, (C2-C8)heteroaryloxy, (C2-C9)heterocycleamino, (C2- Cg)heteroarylamino, amino(C C6)alkoxy, (Cι-C6)alkylamino(C C6)alkoxy, [(Cr C6)alkyl]2amino(C1-C6)alkoxy, amino(CrC6)alkylamino, (C C6)alkylcarbonylamino(C C6)alkylamino, ureido(C C6)alkylamino, hydroxy(C C6)alkylamino, (Cι-C6)alkoxy(CrC6)alkylamino, and (CrC6)alkylsulfonylamino(Cr C6)alkylamino.
Preferred compounds of the formula I include those wherein R1 is halo and a is 1 or 2. Preferred compounds of the formula I include those wherein Y is oxygen. Preferred compounds of the formula I include those wherein Z is oxygen. Preferred compounds of the formula I include those wherein Z is NH. Preferred compounds of the formula I include those wherein W is phenyl. Preferred compounds of the formula I include those wherein W is pyridyl.
Preferred compounds of the formula I include those wherein b is 0, 1 or 2, and R6 is selected from a list consisting of halo, (C C6)alkyl, cyano, or (C 6)alkylcarbonyl.
Preferred compounds of the formula I include those wherein c is 0, and R7 is selected from a list consisting of aminocarbonyl, (C C6)alkylsulfonylamino, (C C6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(C1-C6)alkylaminocarbonyl, (C
C6)alkylaminocarbonyl, hydroxy(C C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C8)heterocycloalkoxy, amino(C2-C9)heteroaryl, (C2-Cg)heteroarylamino, carboxy(C2-C9)heteroarylcarbonyl, ureido(C C6)alkylaminocarbonyl, [(Cr
C6)alkyl]2amino(C1-C6)alkylaminocarbonyl, (CrC^alkylsulfonylaminocarbony^Cr C6)alkoxy, aminocarbonyl(CrC6)alkoxy, or carboxy(C C6)alkoxy.
Preferred compounds of the formula I include those wherein c is 1 , and R7 is selected from a list consisting of (CrC6)alkylsulfonylaminocarbonyl(CrC6)alkoxy, (C2- C9)heteroarylaminocarbonyl(C C6)alkoxy, (CrC6)alkylsulfonylaminocarbonyl, aminocarbonyl, or carboxy. Preferred compounds of the formula I include those wherein R2 and R3 are both methyl groups and R4 and R5are both hydrogen.
Preferred compounds of the formula I include those wherein R2 and R3 are trans and Yand R3 are trans; having relative stereochemistry as shown below.
Figure imgf000006_0001
Preferred compounds of the formula I include those wherein R1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen; R2 and R3 are methyl; R4 and R5 are hydrogen; R2 and R3 are trans; Y and R3 are trans; W is phenyl; b is 0, 1 or 2; R6 is selected from the group consisting of halo, (Cι-C6)alkyl, cyano, or (C1-C6)alkylcarbonyl; c is 0; and R7 is selected from the group consisting of: aminocarbonyl, (CrC-6)alkylsulfonylamino, (CrC6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(d- C6)alkylaminocarbonyl, (C C6)alkylaminocarbonyl, hydroxy(C
C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C9)heterocycloalkoxy, amino(C2-C9)heteroaryl, (C2-C9)heteroarylamino, carboxy(C2-C8)heteroarylcarbonyl, ureido(CrC6)alkylaminocarbonyl, [(C1-C6)alkyl]2amino(CrC6)alkylaminoςarbonyl, (CrCθJalkylsulfonylaminocarbony C-i-C^alkoxy, aminocarbonyl(CrC6)alkoxy, or carboxy(CrC6)alkoxy.
Preferred compounds of the formula I include those wherein R1 halo; a is 1 or 2; Y is oxygen; Z is oxygen or NH, R2 and R3 are methyl; R4and R5 are hydrogen; R2 and R3 are trans; Y and R3 are trans; W is pyridyl; b is 0, 1 or 2; R6 is selected from the group consisting of halo, (CrC6)alkyl, cyano, or (CrC6)alkylcarbonyl; c is 0; and R7 is selected from the group consisting of: aminocarbonyl, (CrC6)alkylsulfonylamino, (Cι-C6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(Cι-C6)alkylaminocarbonyl, (CrC6)alkylaminocarbonyl, hydroxy(C C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C9)heterocycloalkoxy, amino(C2-C9)heteroaryl, (C2-C9)heteroarylamino, carboxy(C2-C9)heteroarylcarbonyl, ureido(Cι-C6)alkylaminocarbonyl, [(Cr
C6)alkyl]2amino(C C6)alkylaminocarbonyl, (CrC6)alkylsulfonylaminocarbonyl(Cr C6)alkoxy, aminocarbonyl(C C6)alkoxy, or carboxy(C C6)alkoxy.
Preferred compounds of the formula I include those wherein R1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen; R2 and R3 are methyl; R4 and R5 are hydrogen; R2 and R3 are trans; Y and R3 are trans; W is phenyl; b is 0, 1 or 2; R6 is selected from the group consisting of: halo, (C C6)alkyl, cyano, or (CrC6)alkylcarbonyl; c is 1 ; and R7 is selected from the group consisting of: (Cr C6)alkylsulfonylaminocarbonyl(C C6)alkoxy, (C2-C9)heteroarylaminocarbonyl(C1- C6)alkoxy, (Cι-C6)alkylsulfonylaminocarbonyl, aminocarbonyl, aminosulfonyl, or carboxy.
Preferred compounds of the formula I include those wherein R halo; a is 1 or 2; Y is oxygen; Z is oxygen or NH, R2 and R3 are methyl; R4 and R5 are hydrogen; R2 and R3 are trans; Yand R3 are trans; W is pyridyl; b is 0, 1 or 2; R6 is selected from the group consisting of: halo, (C C6)alkyl, cyano, or (C C6)alkylcarbonyl; c is 1 ; and R7 is selected from the group consisting of: (C1-C6)alkylsulfonylaminocarbonyl(C C6)alkoxy, (C2-C9)heteroarylaminocarbonyl(C1-C6)alkoxy, (CrC6)alkylsulfonylaminocarbonyl, aminocarbonyl, aminosulfonyl or carboxy.
The most preferred compounds of the formula I are those selected from the group consisting of: 2-(4-Chloro-phenoxy)-1 -(4-phenoxy-piperidin-1 -yl)-ethanone; 2-(4-Chloro-phenoxy)-1-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-ethanone; 5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-benzamide; (5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)- urea;5-Chloro-2-{(2,4-c/'s)-(2,5-frans)- 2-[4-(4-fluoro-phenoxy)-2,5-dimethyl-piperidin-
1 -yl]-2-oxo-ethoxy}-benzamide; (2,4-c/s)-(2,5-frans)-5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetic acid;
N-[(5-Chloro-2-{(2,4-c/s)-(2,5-frat7s)-2-[4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1 -yl]-2-oxo-ethoxy}-phenyl)-acetyl]-methanesulfonamide;
2-(5-Chloro-2-{2-[(2,4-c/s)-(2,5-frans)-4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetamide;
(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)- acetic acid; N-[(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1 -yl]-2-oxo-ethoxy}-phenyl)- acetylj-methanesulfonamide; and
5-Chloro-2-{2-[(2,4-c/s)-(2,5- rans)-4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-benzamide.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant , rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; and sequelae associated with certain cancers such as multiple myeloma. This invention also relates to a pharmaceutical composition for treating or preventing cancer metastasis, including but not limited to breast cancer. This invention also relates to a pharmaceutical composition for preventing production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith). This invention also relates to a pharmaceutical composition for preventing tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria).
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.
The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; and sequelae associated with certain cancers such as multiple myeloma. The present invention also relates to a method for treating or preventing cancer metastasis, including but not limited to breast cancer. The present invention also relates to a method for preventing the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL- 6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith).
The present invention also relates to a method for preventing tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria). , r The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; and sequelae associated with certain cancers such as multiple myeloma. Pharmaceutical compositions of this invention are also potentially useful for the treatment or prevention of cancer metastasis, including but not limited to breast cancer. Pharmaceutical compositions of this invention may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith). Pharmaceutical compositions of this invention may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria) in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes
(recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory, .Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; ' vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; sequelae associated with certain cancers such as multiple myeloma; cancer metastasis, including but not limited to breast cancer; the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith); tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention a CCR1 receptor antagonizing effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. Detailed Description of the Invention PREPARATION A
Figure imgf000014_0001
PREPARATION B
Figure imgf000015_0001
Figure imgf000015_0002
PREPARATION C
Figure imgf000016_0001
PREPARATION D
Figure imgf000017_0001
17
Figure imgf000018_0001
SCHEME 2
Figure imgf000019_0001
SCHEME 3
VII
Figure imgf000020_0001
SCHEME 4
XVII
Figure imgf000021_0001
SCHEME 5
XVII
Figure imgf000022_0001
SCHEME 6
XVII
Figure imgf000023_0001
SCHEME 7
Figure imgf000024_0001
SCHEME 8
XVII
Figure imgf000025_0001
SCHEME 9
Figure imgf000026_0001
In reaction 1 of Preparation A, the compound of formula II is converted to the corresponding compound of formula IV by treating II with a compound of formula III in the presence of a base, such as sodium methoxide and heat.
In reaction 2 of Preparation A, the compound of formula IV is conyβrted to the corresponding compound of formula V by reacting with carbonic acid di-tert- butyl ester in the presence of a base, such as sodium hydroxide, at ambient temperature for a time period between 5 hours and 15 hours, preferably around 12 hours.
In reaction 1 of Preparation B the compound of formula V, which is either commercially available or has been prepared according to Preparations A, is converted to the corresponding compound of formula VI by reacting with a reducing agent, such as L-selectride, in an aprotic solvent, such as tetrahydrofuran, to give a diastereomeric mixture of alcohols, which are separated at this stage by silica gel chromatography. In reaction 2 of Preparation B the desired alcohol is then converted to the corresponding compound of formula VII by treating the alcohol VI with triphenyl phosphine and diethyl azodicarboxylate in the presence of a nucleophile of the formula:
Figure imgf000027_0001
where in Y is oxygen and a is 1 , 2, 3, 4 or 5. Finally, the resulting BOC protecting group on the arylether is removed with trifluoro acetic acid in an aprotic solvent, such as methylene chloride, to give the corresponding compound of formula VII. In the case that Y is NH, a compound of formula V is treated with a compound of the formula:
Figure imgf000027_0002
wherein Y is NH and a is 1 , 2, 3, 4, or 5, in the presence of a reducing agent, such as sodium cyanoborohydride, in the presence of a polar aprotic solvent, such as dichloroethane. Deprotection with trifluoroacetic acid give the corresponding compound of formula VII. In reaction 1 of the Preparation C, the compound of formula VIII is converted to the corresponding compound of formula IX by reacting VIII with an appropriate amine of the formula, HNR8R9, wherein R8 and R9 are each independently selected from a group, including but not limited to, hydrogen, a nitrogen containing (C2- C9)heterocycloalkyl or (C2-C9)heteroaryl group, or an optionally substituted (C C6)alkyl, or R18 and R19 are taken together with the nitrogen to which they are attached to form (C2-Cg)heterocycloalkyl or (C2-Cg)heteroaryl group, in the presence of a polar aprotic solvent, such as methylene chloride. The reaction mixture is stirred, at ambient temperature, for a time period between about 1 hour to about 24 hours, preferably about 12 hours.
In reaction 2 of Preparation C, the compound of formula IX is converted to the corresponding compound of formula X by reacting IX with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide. The reaction is heated to reflux for a time period between about 1 hour to about 10 hours, preferably about 4 hours.
In reaction 3 of Preparation C, the compound of formula VIII is converted to the corresponding compound of formula XI by reacting VIII with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile. The reaction is stirred, at ambient temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours. An appropriate amine of the formula HNR8R9, wherein R8 and R9 are each independently selected from a group, including but not limited to, hydrogen, a nitrogen containing (C2-Cg)heterocycloalkyl or (C2- C9)heteroaryl group, or an optionally substituted (C C6)alkyl, or R18 and R19 are taken together with the nitrogen to which they are attached to form (C2-C9)heterocycloalkyl or (C2-C9)heteroaryl group, is then added and the reaction mixture so formed is stirred, at ambient temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
In reaction 4 of Preparation C, the compound of formula XI is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Preparation C.
In reaction 1 of Preparation D the compound of formula XIII is converted to the corresponding compound of the formula XIV by treating with a reducing agent, such as lithium aluminum hydride, in an aprotic solvent, such as tetrahydrofuran. The reaction mixture is heated to reflux for a time period between 1 hour and 6 hours, preferably about 2 hours.
In reaction 2 of Preparation D the compound of formula XIV is converted to the corresponding compound of the formula XV by first treating with an activating agent such as sulfonyl chloride, in the presence of an aprotic solvent, ' such as chloroform. The reaction is heated to reflux, for a time period between about 1 hour to about 10 hours, preferably about 3 hours. The resulting alkyl chloride is then treated with a cyanide source, such as potassium cyanide, in the presence of an aprotic solvent, such as acetonitrile. The reaction mixture is stirred at ambient temperature for a time period between about 1 hour to about 10 hours, preferably about 3 hours.
In reaction 3 of Preparation D the compound of formula XV is converted to the compound of formula XVI, wherein j is 1, by first treating XV with base, such as potassium hydroxide in water. The reaction mixture is heated to reflux for a time period between about 1 hour to about 10 hours, preferably about 6 hours. The resulting carboxylic acid is treated with acid, such as 47% aqueous hydrogen bromide to produce the deprotected phenol. The reaction mixture is heated to reflux for a time period between about 10 hours to about 30 hours, preferably about 24 hours. The deprotected phenol is finally converted to the corresponding compound of formula XVI, wherein j is 1, by refluxing in ethanol in the presence of an acid, such as sulfuric acid, for a time period between about 8 hours to about 16 hours, preferably about 12 hours.
In reaction 4 of Preparation D the compound of formula XIII is converted to the corresponding compound of formula XVI, wherein j is 2 or 3, by first treating the ester with a reducing agent, such as diisobutylaluminum hydride, in the presence of an aprotic solvent, such as toluene. The resulting aldehyde is treated with a phosphonium ylide derived from the phosphonium salt of the formula
Figure imgf000029_0001
wherein g is 1 or 2, in the presence of an aprotic solvent, such as tetrahydrofuran. The reaction is refluxed for a time period between about 4 hours to about 16 hours, preferably about 10 hours. The resulting olefin is then reduced by shaking under a positive pressure of hydrogen in the presence of a catalyst, such as 20% palladium hydroxide on carbon, in the presence of a protic solvent such as ethanol. The methyl ether is deprotected according to the procedure described for reaction 3 of Preparation D.
In reaction 1 of Scheme 1, the compound of formula VII is converted to the corresponding compound of formula XVII by reacting VII with a compound of the formula, A-(C=O)-(CH2)-A, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about -10°C to about 10°C, for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
In reaction 2 of Scheme 1, the compound of formula XVII is converted to the corresponding compound of formula I by reacting XVII with a compound of the formula
Figure imgf000030_0001
wherein Z is oxygen, which is either commercially available or is prepared according to Preparations D and E, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone. The reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
In reaction 1 of Scheme 2, the compound of formula VII is converted to the corresponding compound of formula I by reacting VII with a compound of the formula
Figure imgf000030_0002
wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about -10°C to about 10°C, for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
In reaction 1 of Scheme 3, the compound of formula VII is converted to the corresponding compound of formula XVIII by reacting VII with an carboxylic acid of the formula:
Figure imgf000030_0003
wherein Z-P is O-(C=O)-CH3 or -NH-(C=O)-O-tBu, in the presence 4- dimethylaminopyridine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. In the case when Z-P is O-(C=O)-CH3 then the resulting acetate is treated with base such as lithium hydroxide in,, a protic solvent such as a mixture of tetrahydrofuran, water and methanol, to give a compound of the formula XVIII. In the case when Z is -NH-(C=O)-O-tBu, the resulting amide is treated with an acid, such as trifluoroacetic acid, in an aprotic solvent, such as dichloromethane to give the compound of the formula XVIII.
In reaction 2 of Scheme 3, the compound of formula XVIII wherein Z is oxygen, or NH, is converted to the corresponding compound of formula I where W is a (C2-C9)heteroaryl group, by reacting with a compound of formula Hal-W, wherein Hal is a chloro or bromo and W is an appropriately functionalized heteroaryl group, in the presence of a base, such as sodium hydride, in an aprotic solvent, such as tetrahydrofuran. In reaction 1 of Scheme 4, the compound of formula XVII is converted to the corresponding compound of formula XIX according to the procedure described above in reaction 2 of Scheme 1.
In reaction 2 of Scheme 4, the compound of formula XIX is converted to the corresponding compound of formula XX by reacting XIX with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at ambient temperature.
In reaction 3 of Scheme 4, the compound of formula XX is converted to the corresponding amide or acylsulfonamide of formula I, by reacting XX with an appropriate amine or sulfonamide in the presence of 4-dimethylaminopyridine, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. The resulting reaction mixture is stirred overnight at ambient temperature.
In reaction 1 of Scheme 5, the compound of formula XVII is converted to the corresponding compound of formula XXI according to the procedure described above in reaction 2 of Scheme 1
In reaction 2 of Scheme 5, the compound of formula XXI is converted to the corresponding compound of formula XXII by hydrogenating XXI in the presence of a catalyst, such as platinum on carbon, and a polar protic solvent, such as ethanol. The reaction is carried out under a positive pressure of hydrogen gas between about 30 psi to about 40 psi, preferably about 35 psi, for a time period between about 15 minutes to about 1 hour, preferably 30 minutes.
In reaction 3 of Scheme 5, the compound of formula XXII is converted to the corresponding urea of formula I, by first reacting XXII with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an appropriate amine. The reaction mixture, so formed, is allowed to stir overnight at ambient temperature. To form the sulfonamides of formula I, the compound of formula XXII is reacted with an appropriate sulfonyl chloride in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
The reaction is stirred overnight at ambient temperature. To prepare cyanoguanidines of the formula I, the compound of formula XXII is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate. The resulting reaction mixture is heated to reflux overnight. The N-cyano-S-methyl- isothiourea intermediate is then reacted with an appropriate amine in the presence of a polar protic solvent, such as methanol, to form the cyanoguanidine of formula I. For the preparation of amides or the formula I, the compound of formula XXII is reacted with an appropriate acid in the presence of N-methylmorpholine, O-benzotriazole-1- yl-N,N,N ,N -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride, to form the amide of formula I. For secondary amine formation the compound of formula XXII is reacted with an appropriate aldehyde in the presence of a reducing agent, such as sodium triacetoxyborohydride, in the presence of a polar solvent, such as methanol. In reaction 1 of Scheme 6, the compound of formula XVII is converted to the corresponding compound of formula XXIII, according to the procedure described above in reaction 2 of Scheme
In reaction 2 of Scheme 6, the compound of formula XXIII is converted to the corresponding compound of formula I by reacting XXIII with an appropriate amine in the presence of a 10:1 ratio solution of dichloroethane/acetic acid. The reaction mixture is stirred, at ambient temperature, for a time period between about 30 minutes to about 2 hours, preferably about 1 hour. A reducing agent, such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at ambient temperature. If the amine thus formed is secondary, the compound of formula I may further be reacted according to the procedure described above in reaction 3 of Scheme 5, to provide ureas, sulfonamides, cyanoguanidines, or amides.
In reaction 1 of Scheme 7, the acid compound of formula XX is conyerted to the corresponding compound of formula XXIV by treating XX with thionyl chloride neat or in an aprotic solvent, at ambient temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour. The acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H3CO)(H3C)NH»HCI, in the presence of an amine base, such as triethylamine. The reaction mixture is stirred, at ambient temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
In reaction 2 of Scheme 7, the amide compound of formula XXIV is converted to the corresponding compound of formula I by reacting XXIV with a (C2-C9)heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about -100°C to ambient temperature, preferably about -78°C. The resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hours, preferably about 12 hours, at a temperature between about -78°C to about 50°'C, preferably about 20°C.
In reaction 1 of Scheme 8, the compound of formula XVII is converted to the corresponding compound of formula XXV, wherein j is 1 , 2, or 3, according to the procedure described above in reaction 2 of Scheme 1..
In reaction 2 of Scheme 8, the compound of formula XXV, wherein j is 1 , 2, or 3, is converted to the corresponding compound of formula XXVI, wherein j is 1 , 2, or 3, according to the procedure described above in reaction 2 of Scheme 4. In reaction 3 of Scheme 8 the compound of formula XXVI, wherein j is 1 , 2, or
3, is converted to the corresponding amide or acylsulfonamide of the formula I, wherein j is 1 , 2, or 3, by treating with an appropriate amine or sulfonamide according to the procedure described above in reaction 3 of Scheme 4. The compound of formula XXVI, wherein j is 1 , 2, or 3, is converted to other compounds of formula I according to the procedures described above for Scheme 7.
In reaction 1 of Scheme 9 the compound of formula XXV, wherein j is 0, 1 , 2, or 3, is converted to the corresponding compound of formula XXVII wherein j is 0, 1 , 2, or 3, by reacting with a reducing agent, such as sodium borohydride, in a protic solvent, such as tert-butyl alcohol. In reaction 2 of Scheme 9 the compound of formula XXVII, wherein j is 0, 1, 2, or 3, is converted to the corresponding compound of formula I by first treating with thionyl chloride, in the presence of an aprotic solvent, such as chloroform. The reaction is heated to reflux, for a time period between about 1 hour to about 10 hours, preferably about 3 hours. The resulting alkyl chloride is then treated with sodium sulfite in a polar protic solvent, such as ethanol and water, and heated to a temperature between 90°C and 150°C, preferably around 110°C, for a time period between 10 and 20 hours, preferably 12 hours. To prepare sulfonamides or the formula I, the resulting sulfonate is treated with phosphorous pentachloride in an aprotic solvent, such as toluene, at a temperature between ambient and reflux, preferably at reflux for a time period between 1 hour and 8 hours, preferably 3 hours to give the corresponding sulfonyl chloride. The sulfonyl chloride is then reacted with an appropriate amine in a polar aprotic solvent, such as tetrahydrofuran, at ambient temperature for a time period between 3 hours and 24 hours, preferably 12 hours. The sulfonamide can be taken on further to acylsulfonamides of the formula I by treating with an acid chloride in the presence of base, such as triethylamine, in a aprotic solvent, such as dichloromethane, at ambient temperature.
Unless otherwise indicated, the pressure of each of the above reactions is not critical. Generally, the reactions are conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
The compounds of the formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating the basic compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, a solid salt is obtained.
The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [La, 1 ,1 '-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
Those compounds of the formula I that are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non- toxic base salts with the herein described acidic compounds of formula I. These non- toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
The present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium. Unless otherwise indicated, the alkyl groups referred to herein may be linear or branched, and they may also be cyclic (e.g.. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) or bicyclic (e.g., norbomanyl, bicyclo [3.2.1]octane) or contain cyclic groups. They may also contain zero to two levels of unsaturation and may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of but not limited to: halo-, HO-, NC-, H2N-, HO-(C=O)-.
Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.
(C2-C9)Heterocyclyl- when used herein refers to, but is not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1 ,3- oxazolidin-3-yl, isothiazolidinyl, 1 ,3-thiazolidin-3-yl, 1 ,2-pyrazolidin-2-yl, 1 ,3- pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1 ,2-tetrahydrothiazin-2-yl, 1 ,3- tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-tetrahydrodiazin-2-yl, 1 ,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl and chromanyl. Said (C2- C9)heterocyclyl ring is attached through a carbon or a nitrogen atom. (C2-C9)Heteroaryl when used herein refers to, but is not limited to, furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1 ,3,5-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,5- thiadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1 ,2,3-triazinyl, 1 ,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl and benzoxazinyl. and may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of, but not limited to: H-, HO-, halo-, (C1-C8)alkyl- optionally substituted with 1-3 fluorine atoms, (C1-C8)alkyl-O- wherein the alkyl group is optionally substituted with 1 -3 fluorine atoms, HO-(C1 -C8)alkyl-, NC-, H2N-, H2N-(C1 -C8)alkyl-, HO-(C=O)-, (C1 - C8)alkyl-(C=O)-, (C1-C8)alkyl-(C=O)-(C1-C8)alkyl-, H2N-(C=O)-, H2N-(C=O)-(C1- C8)alkyl-, H2NSO2-, (C1-C8)alkyl-SO2-NH-.
Aryl when used herein refers to phenyl or naphthyl which may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of but not limited to: H-, HO-, halo-, (C1-C8)alkyl- optionally substituted with 1-3 fluorine atoms, (C1-C8)alkyl-O- wherein the alkyl group is optionally substituted with 1-3 fluorine atoms, HO-(C1-C8)alkyl-, NC-, H2N-, H2N-(C1-C8)alkyl-, HO-(C=O)-, (C1- C8)alkyl-(C=O)-, (C1-C8)alkyl-(C=O)-(C1-C8)alkyl-, < H2N-(C=O)-, H2N-(C=O)-(C1- C8)alkyl-, H2NSO2-, (C1-C8)alkyl-SO2-NH-;
This invention also encompasses pharmaceutical compositions containing and methods of treating or preventing comprising administering prodrugs of compounds of the formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring arηipo acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain. This invention also provides for introduction of hydrogen isotopes (i.e., deuterium, tritium) by replacing 1H2 with 2H2 or 3H2 in the above procedure.
The compounds of this invention include all conformational isomers (e.g.. cis and trans isomers. The compounds of the present invention have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them. In this regard, the invention includes both the E and Z configurations. The compounds of formula I may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as "the active compounds") are potent inhibitors of MIP-1 α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor. These compounds also inhibit MIP-1 (and the related chemokines shown to interact with CCR1 (e.g.. RANTES (CCL5), MCP-2 (CCL8), MCP-3 (CCL7), HCC-1 (CCL14) and HCC-2 (CCL15))) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment and prevention of the following disorders and conditions: autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, juvenile arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, neuroimmunologic disease (multiple sclerosis (MS) primary progressive MS, secondary progressive MS, chronic progressive MS, progressive relapsing MS, relapsing remitting MS, worsening MS), polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (such as pulmonary fibrosis (for example idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic inflammatory conditions including ocular inflammation, stenosis, lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis), vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to, restenosis following angioplasty and/or stent insertion) and other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and chronic transplant rejection (including xeno-transplantation); HIV infectivity (co- receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); Alzheimer's disease; chronic fatigue syndrome; pain; atherosclerosis; conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); and sequelae associated with certain cancers such as multiple myeloma. This method of treatment may also have utility for the prevention of cancer metastasis, including but not limited to breast cancer.
This method of treatment may also inhibit the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith). This method of treatment may also prevent tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-
3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and,, Herpes simplex) fungal meningitis, lyme disease, malaria).
The activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E.,
Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. editors: Current Protocols In Immunology. 6.12.1- 6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.
Chemotaxis Assay:
The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI
(BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1 (Peprotech, Inc., P.O. Box 275, Rocky Hill NJ) or other test agonists, are placed into the lower chambers of the Boyden chamber. A polycarbonate filter is then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1 should be adequate).
THP-1 cells (ATCC TIB-202), primary human monocytes, or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound.
Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.
After a suitable incubation period at 37 degrees centigrade (e.g. 3.5 hours for
THP-1 cells, 90 minutes for primary monocytes), the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
For THP-1 cells, the chamber (a 96 well variety manufactured by
Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.
For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.
The number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound). The quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used. The 50% inhibition point is then determined using a line fit analysis for all concentrations tested. The line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a valid assay.
All of the compounds of the invention illustrated in the following examples had IC50 of less than 10μM, in the Chemotaxis assay. The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g.. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g.. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g.. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, αg^, in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
Aerosol formulations for treatment of the conditions referred to above (e.g., rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or "puff' of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time. The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626,
3,119,742, and 3,492,397.
The compounds of the invention may also be utilized in combination therapy with other therapeutic agents such as those that inhibit immune cell activation and/or cytokine secretion or action (i.e. Cyclosporin A, ISAtx247, Rapamycin, Everolimus, FK-506, Azathioprine, Mycophenolate mofetil, Mycophenolic acid, Daclizumab, Basiliximab, Muromonab, Horse anti-thymocyte globulin, Polyclonal rabbit antithymocyte globulin, Leflunomide, FK-778 (MNA-715), FTY-720, BMS- 188667 (CTLA4-lg), BMS-224818 (CTLA4-lg), RG-1046 (CTLA4-lg), Prednisone, Prednisolone, Methylprednisolone suleptanate, Cortisone, Hydrocortisone, Methotrexate, Sulfasalazine, Etanercept, Infliximab, Adalimumab (D2E7), CDP- 571 , CDP-870, Anakinra, Anti-interleukin-6 receptor monoclonal antibody (MRA)), NSAIDS (aspirin, acetaminophen, naproxen, ibuprofen, ketoprofen, diclofenac and piroxicam), COX-2 inhibitors (Celecoxib, Valdecoxib, Rofecoxib, Parecoxib, Etoricoxib, L-745337, COX-189, BMS-347070, S-2474, JTE-522, CS-502, P-54, DFP), Glatiramer acetate, Interferon beta 1-a, Interferon beta 1-b, Mitoxantrone, Pimecrolimus, or agents that inhibit cell recruitment mechanisms (eg inhibitors of integrin upregulation or function) or alter leukocyte trafficking.
EXAMPLES
The following examples are put forth so as to provide those of ordinary skill in the art with a disclosure and description of how the compounds, compositions, and methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, percent is percent by weight given the component and the total weight of the composition, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric. Commercial reagents were utilized without further purification. Example 1
(+)-2-(5-Chloro-2-f(2.4-c/s)-(2.5-frat7s)-2-r4-(4-fluoro-phenoxy)-2.5-dimethyl- piperidin-1-vπ-2-oxo-ethoxy}-phenyl)-acetamide
(5-Chloro-2-methoxy-phenyl)-methanol
To a solution of 5-chloro-2-methoxy-benzoic acid methyl ester (20 grams, 9.97 mmol) in THF (100 mL) at 0°C was added dropwise a solution of lithium aluminum hydride (210 mL, 210 mmol, 1M soln. in THF). The solution was then warmed to reflux for 2 hours. The reaction was cooled to 0°C and carefully quenched by the addition of cold water. The mixture was filtered through celite and the filter cake was washed with diethyl ether. The filtrate was washed with saturated aqueous sodium hydrogen carbonate then dried over magnesium sulfate. Concentration in vacuo gave the title compound (17.24 grams).
(5-Chloro-2-methoxy-phenyl)-acetonitrile
To a solution of (5-chloro-2-methoxy-phenyl)-methanol (17.1 grams, 99.06 mmol) in methylene chloride (100 mL) was added thionyl chloride (14.5 mL).' The reaction was stirred at reflux for 3 hours, cooled to room temperature and concentrated in vacuo. The crude product was dissolved in methylene chloride and washed with saturated aqueous sodium hydrogen carbonate then dried over magnesium sulfate. Concentration in vacuo gave the benzyl chloride intermediate (18.43 grams). To a solution of the chloro compound in acetonitrile (100 mL) was added potassium cyanide (12.5 grams, 193 mmol) and 18-crown-6 (2.54 grams, 9.64 mmol). The reaction was stirred 12 hours at ambient temperature, diluted with ethyl acetate and washed with aqueous sodium hydrogen carbonate. The organics were dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by passing it through a pad of silica gel, eluting with methylene chloride, thus giving the title compound (17.2 grams).
(5-Chloro-2-methoxy-phenyl)-acetic acid
To a solution of (5-chloro-2-methoxy-phenyl)-acetonitrile (17.2 grams, 96.3 mmol) in ethanol (200 mL) and water (20 mL) was added potassium hydroxide (27 grams, 481 mmol). The reaction was heated to reflux for 12 hours, cooled and concentrated in vacuo. The remaining solution was made acidic with aqueous hydrochloric acid (3 M) and extracted with diethyl ether. The organics were dried over magnesium sulfate and concentrated in vacuo to give the title compound (15.65 grams).
(5-Chloro-2-hvdroχy-phenyl)-acetic acid ethyl ester
A solution of (5-chloro-2-methoxy-phenyl)-acetic acid (15.54 grams, 77.5 mmol) in 48% aqueous hydrogen bromide was heated to reflux for 20 hours. The solution was cooled, diluted with water and extracted with diethyl ether. The organics were dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by trituration in 2:1 methylene chloride:hexanes to give (5- chloro-2-hydroxy-phenyl)-acetic acid (12.78 grams). This was dissolved in a solution of ethanol saturated with hydrochloric acid and stirred 12 hours. The reaction was concentrated in vacuo, then the crude product was dissolved in diethyl ether and washed with saturated aqueous sodium hydrogen carbonate. The organics were dried over magnesium sulfate and concentrated in vacuo to give the title compound (12.7 grams).
(fra/?s)-2,5-Dimethyl-piperidin-4-one
To a solution of 3-amino-butyric acid ethyl ester (20 ml, 149 mmol) in 2- propanol (8 ml) was added 2-methyl-acrylic acid methyl ester (17 ml, 159 mmol) and ammonium chloride (500 mg, 9.3 mmol). The reaction was refluxed for 4 hours, cooled and concentrated in vacuo to give 3-(2-methoxycarbonyl- propylamino)-butyric acid ethyl ester. The 3-(2-methoxycarbonyl-propylamino)- butyric acid ethyl ester was dissolved in toluene (100 ml) and heated to reflux. To this was added a 25 % by weight solution of sodium methoxide in methanol (35 ml, 0.135 mmol) via drop funnel. The reaction was fitted with a condenser and methanol was azeotroped off at a vapor pressure of 100 to 110°C. After the methanol was azeotroped off, the reaction was heated at 110°C for one hour. The reaction was then cooled to ambient temperature, treated with concentrated hydrochloric acid (50 ml), and refluxed for 3 hours. The reaction was cooled to ambient temperature and neutralized with solid sodium hydrogen carbonate. The reaction was cooled to 0°C and saturated aqueous sodium hydroxide was then added until pH = 11 was achieved. After stirring for one hour, the reaction was extracted with chloroform (3 times). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated. The crude product was purified by vacuum distillation to give the title compound (3.68 grams, 21% yield).
(2,5-frans)-2,5-Dimethyl-4-oxo-piperidine-1 -carboxylic acid tert-butyl ester r |, To a solution of (fraπs)-2,5-dimethyl-piperidin-4-one (3.68 grams, 28.9 mmol) in tert-butyl alcohol (50 ml) and water (50 ml) was added sodium hydroxide (2.0 grams, 50 mmol) and di-tert-butyl-dicarbonate (7.0 grams, 32 mmol). The reaction was stirred at ambient temperature overnight. The reaction was diluted with water and extracted with diethyl ether (3 times). The organic layers were combined, dried over magnesium sulfate and concentrated to give the title compound (4.33 grams, 60 % yield).
(2, 4-frans)-(2,5-frans)-4-Hvdroxy-2,5-dimethyl-piperidine-1 -carboxylic acid tert-butyl ester and (2,4-c/s)-(2,5-frat?s)- 4-Hvdroxy-2,5-dimethyl-piperidine-1 -carboxylic acid tert-butyl ester
To a solution of (trans)-2,5-dimethyl-4-oxo-piperidine-1 -carboxylic acid tert- butyl ester (2.08 grams, 9.15 mmol) in tetrahydrofuran (35 ml) at -78°C Under nitrogen was added L-selectride (15 ml, 15 mmol) via addition funnel. The reaction was stirred at -78°C for 3 hours and then quenched with a phosphate buffer (pH=7). The reaction was extracted with ethyl acetate (2 times). The organic layers were combined, washed with brine, then dried over magnesium sulfate, filtered and concentrated. The crude product was purified by chromatography on silica gel to give the title compounds: (2A-trans)-(2,5-trans) (1.1 grams, 52 % yield) and (2,4-c/s)-(2,5-frar/s) (2.41 grams, impure).
(2.4-c/s)-(2,5-fra/?s)-4-(4-Fluoro-phenoxy)-2,5-dimethyl-piperidine-1 -carboxylic acid tert-butyl ester
To a solution (2,4-c/s)-(2,5-frans)-4-hydroxy-2,5-dimethyl-piperidine-1- carboxylic acid tert-butyl ester (1.1 grams, 4.79 mmol) in tetrahydrofuran (25 ml) was added triphenyl phosphine (1.91 grams, 7.28 mmol), 4-fluoro-phenol (865 mg, 7.7 mmol) and diethyl azidocarboxylate (1.2 ml, 7.6 mmol). The reaction was stirred overnight at ambient temperature. The reaction was then concentrated and purified by chromatography on silica gel giving the title compound (500 mg, 32 % yield). O 2004/009550
45
(2,4-c/s)-(2,5-frat?s) -2-Chloro-1-f4-(4-fluoro-phenoxy)-2,5-dimethyl-piperidin-1-yl1- ethanone
To a solution of (2,4-c/s)-(2,5-£rans)-4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidine-1 -carboxylic acid tert-butyl ester (500 mg, 1 ,54 mmol) in dichloromethane
(15 ml) was added trifluoroacetic acid (1.5 ml). The reaction was stirred at ambient temperature for 2 hours. The reaction was quenched with saturated aqueous sodium hydrogen carbonate and extracted with dichloromethane (2 times). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The resulting residue was dissolved in methylene chloride (10 ml), and treated with triethylamine (325 μL, 2.33 mmol) and chloroacetyl chloride (150 μL, 1.96 mmol).
The reaction was stirred at ambient temperature for 3 hours, concentrated in vacuo, and purified by chromatography on silica gel to give the title compound (301 mg, 65
% yield).
(2,4-c/s)-(2,5-trar/s)-(5-Chloro-2-f2-f4-(4-fluoro-phenoxy)-215-dimethyl-piperidin-1- yll-2-oxo-ethoxy)-phenyl)-acetic acid ethyl ester
To a solution of (2,4-c/s)-(2,5-frans)-2-chloro-1-[4-(4-fluoro-phenoxy)-2,5- dimethyl-piperidin-1-yl]-ethanone (150 mg, 0.50 mmol) in 2-butanone (1ml) was added (5-chloro-2-hydroxy-phenyl)-acetic acid ethyl ester (125 mg, 0.58 mmol), potassium carbonate (175 mg, 1.26 mmol) and potassium iodide (85 mg, 0.512 mmol). The reaction was heated at 60°C overnight. The reaction was cooled, diluted with water and extracted with ethyl acetate (2 times). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (174 mg, 73 % yield).
(5-Chloro-2-((2.4-c/s)-(2.5-frans)-2-r4-(4-fluoro-phenoxy)-2.5-dimethyl-piperidin-1- vπ-2-oxo-ethoxy)-phenyl)-acetic acid
To a solution of (2,4-c/'s)-(2,5-fra7s)-(5-chloro-2-{2-[4-(4-fluoro-phenoxy)-2,5- dimethyl-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetic acid ethyl ester (170 mg, 0.355 mmol) in a solution of tetrahydrofuran (1 ml), methanol (1 ml) and water (0.5 ml) was added lithium hydroxide monohydrate (22 mg, 0.523 mmol). The reaction was stirred at ambient temperature for three hours. The reaction was diluted with ethyl acetate and washed with 0.2 M aqueous hydrochloric acid solution and brine. The 46
organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was triterated in diethyl ether to give the title compound (163.3 mg, 100 % yield).
(2,4-c/s)-(2.5-frat?s)-2-(5-Chloro-2-(2-r4-(4-fluoro-phenoxy)-2,5-dimethyl-piperidin-1- yll-2-oxo-ethoxy)-phenyl)-acetamide
To a solution of (2,4-c/s)-(2,5-fraπs)-(5-chloro-2-{2-[4-(4-fluoro-phenoxy)-2,5- dimethyl-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetic acid (50.6 mg, 0.112 mmol) in dichloromethane (1 ml) was added thionyl chloride (11 μl, 0.15 mmol). The reaction was stirred at ambient temperature for 2 hours. The reaction is cooled to 0°C and quenched with ammonium hydroxide (2 ml, 33%) and allowed to warm to ambient temperature over 3 hours. The reaction was diluted with water and extracted with dichloromethane (2 times). The organics were combined, dried over magnesium sulfate, filtered, concentrated in vacuo and triturated in diethyl ether to give the title compound (48.2 mg, 95 % yield, LRMS M+H 449.2).
The title compounds for Example 2-4 were prepared by a method analogous to that described in Example 1.
Figure imgf000047_0001
Figure imgf000048_0001
Example 5 (5-Chloro-2-f2-f4-(4-fluoro-phenoxy)-piperidin-1-vn-2-oxo-ethoxy)-phenyl)- urea
4-Hvdroxy-piperidine-1 -carboxylic acid tert-butyl ester
To a solution of sodium hydroxide (12.6 grams, 31.5 mmol)) in water (25 ml) was added tert-butyl alcohol (25 ml), piperidin-4-ol (2.04 grams, 20.17 mmol) and di-tert-butyl-dicarbonate (5.07 grams, 23.23 mmol). The reaction was stirred at ambient temperature overnight. The reaction was diluted with 0.2 M aqueous hydrochloric acid and extracted with ethyl acetate (2 times). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (4.57 g, > 100%).
4-(4-Fluoro-phenoxy)-piperidine-1 -carboxylic acid tert-butyl ester
To a solution of 4-hydroxy-piperidine-1 -carboxylic acid tert-butyl ester (4 grams, 19.8 mmol) in tetrahydrofuran (80 ml) was added 4-fluoro phenol (2.62 grams, 23.3 mmol), triphenyl phosphine (6.25 grams, 23.3 mmol), and diethyl azidocarboxylate (3.8 ml, 24.1 mmol). The reaction was stirred at ambient temperature overnight. The reaction was diluted with dichloromethane and washed with 0.2M aqueous sodium hydroxide. The organic layer was separated, dried over magnesium sulfate and concentrated to give a yellow oil. Chromatography on silica gel gave the title compound (4.08 grams, 70 % yield).
4-(4-Fluoro-phenoxyVpiperidine
To a solution of 4-(4-fluoro-phenoxy)-piperidine-1 -carboxylic acid tert-butyl ester (2.04 grams, 6.91 mmol) in dichloromethane was added trifluoroacetic acid (3 ml). The reaction was stirred at ambient temperature for 2.5 hours. The reaction was concentrated, diluted with dichloromethane and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated to give the title compound (1.24 grams, 92 % yield). 2-Chloro-1-r4-(4-fluoro-phenoxy)-piperidin-1-yll-ethanone
To a solution of 4-(4-fluoro-phenoxy)-piperidine (1.24 grams, 6.36 mmol) in dichloromethane was added triethyl amine (1.2 ml, 8.6 mmol) and chlqroacetyl chloride (0.54 ml, 7.0 mmol). The reaction was stirred at ambient temperature for
30 minutes. The reaction was concentrated in vacuo and purified by silica gel chromatography to give the title compound (1.22 grams, 71 % yield).
2-(4-Chloro-2-nitro-phenoxy)-1-r4-(4-fluoro-phenoxy)-piperidin-1-yll-ethanone To a solution of 2-chloro-1-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-ethanone
(594 mg, 2.188 mmol) in 2-butanone (10 ml) was added 4-chloro-2-nitro-phenol (427 mg, 2.46 mmol), potassium carbonate (655 mg, 4.74 mmol) and potassium iodide (372 mg, 2.24 mmol). The reaction was refluxed overnight. The reaction was then cooled, concentrated in vacuo and purified by silica gel chromatography to give the title compound (699 mg, 78 % yield).
2-(2-Amino-4-chloro-phenoxy)-1-r4-(4-fluoro-phenoxy)-piperidin-1-vn-ethanone'
To a solution of 2-(4-chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-phenoxy)- piperidin-1-yl]-ethanone (699 mg, 1.71 mmol) in ethanol (50 ml) was added platinum on carbon (65 mg, 5 % on carbon). The reaction was subject to 30 psi hydrogen gas overnight. The reaction mixture was filtered through a 0.54 μM filter and concentrated in vacuo to give the title compound (611 mg, 94 % yield).
(5-Chloro-2-(2-r4-(4-fluoro-phenoxy)-piperidin-1-vn-2-oxo-ethoxy)-phenyl)-urea To a solution of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-phenoxy)- piperidin-1-yl]-ethanone (65 mg, 0.171 mmol) in dichloromethane (1 ml) was added triethylamine (60 μl, 0.429 mmol) and phenylchloroformate (36 μl, 0.286 mmol). The reaction was stirred at ambient temperature for 4 hours. The reaction was then concentrated in vacuo, and the resulting residue dissolved in methanol (4 ml) followed by bubbling in ammonia gas for 10 minutes. The reaction was capped and stirred overnight at ambient temperature. The reaction was then concentrated in vacuo and purified by silica gel chromatography to give the title compound (53.1 mg, 73%, LRMS M+H = 421.9). The title compounds for Example 6-10 were prepared by a method analogous to that described in Example 5.
Figure imgf000050_0001
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application for all purposes.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Claims

CLAIMS What is claimed is:
1. A compound of the formula
Figure imgf000051_0001
or pharmaceutically acceptable salts, tautomers, and pro-drugs thereof; wherein a is 1 , 2, 3, 4 or 5; b is O, 1 , 2, 3, or 4; c is 0 or 1 ; Q is (C-ι-Cβ)alkyl;
W is (C6-Cιo)aryl or (C2-C9)heteroaryl; Y is oxygen, or NR8 wherein R8 is hydrogen or (CrC6)alkyl; Z is oxygen or NR9, where R9 is hydrogen, (CrC6)alkyl, or acetyl; each R1 is independently selected from the group consisting of: hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C C6)alkyl, hydroxy, (d- C6)alkylcarbonyloxy, and (CrC6)alkoxy;
R2 , R3, R4 and R5 are each independently hydrogen or (C C6)alkyl optionally substituted with 1 to 3 halo groups; each R6 is independently selected from a list consisting of: hydrogen, halo, (C C6)alkyl optionally substituted with 1 to 3 halo groups; cyano, (C C6)alkoxy, aminocarbonyl, carboxy, (CrC6)alkylcarbonyl, or (C C6)alkoxy optionally substituted by 1 to 3 halo groups; and
R7 is selected from a list consisting of hydrogen, halo, (C C6)alkyl optionally substituted with 1 to 3 halo groups, [(C C6)alkyl]2amino(CrC6)alkylaminocarbonyl, amino(Cι-C6)alkylaminocarbonyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonyl cyano, (C-ι-C6)alkoxy, aminocarbonyl, (C1-C6)alkylaminocarbonyl, [(Cr C6)alkyl]2aminocarbonyl, (CrC6)alkylsulfonylamino, (C C6)alkylsulfonylaminocarbonyl, ureido, aminosulfonyl, [(CrC6)alkyl]2aminosulfonyl, (Cι-C6)alkylaminosulfonyl, [(C1-C6)alkyl]2aminocarbonyl(C1-C6)alkylaminocarbonyl, (C C6)alkylaminocarbonyl(CrC6)alkylaminocarbonyl, aminocarbonyl(d- C6)alkylaminocarbonyl, (CrC6)alkylsulfonylamino, hydroxy(d- C6)alkylcarbonylamino, ureido(CrC6)alkylaminocarbonyl, [(CrC6)alkyl]2ureido(C1- C6)alkylaminocarbonyl, (C1-C6)alkylureido(C1-C6)alkylaminocarbonyl, (C2- Cg)heteroarylaminocarbonyl, carboxy, (CrC6)alkoxy(Cι-C6)alkyl(C2- Cg)heterocyclecarbonyl, (C2-C9)heterocyclecarbonyl, hydroxy(C2-
Cg)heterocyclecarbonyl, aminocarbonyl(C2-C9)heterocyclecarbonyl, carboxy(C2- C9)heterocyclecarbonyl, amino(C2-C9)heteroaryl(CrC6)alkyl, (C C6)alkylamino(C2- Cg)heteroaryl(CrC6)alkylr [(C1-C6)alkyl]2amino(C2-Cg)heteroaryl(C1-C6)alkyl, (C2- Cg)heteroarylamino(Cι-C6)alkyl, (C2-C9)heteroarylaminocarbonyl(C1-C6)alkoxy, (C C6)alkylsulfonylaminocarbonyl(CrC6)alkoxy, aminocarbonyl(C C6)alkoxy, carboxy(C1-C6)alkoxy, aminosulfonyl, (CrC6)alkylcarbonylaminosulfonyl, hydroxy(CrC6)alkylcarbonylaminosulfonyl, (d-C^alkoxycarbonylaminosulfonyl, (C C6)alkoxy(Cι-C6)alkylcarbonylaminosulfonyl, hydroxysulfonyl, hydroxy, hydroxy(CrC6)alkylaminocarbonyl, carboxy(C2-C9)heterocycloxy or [carboxy][amino](Cι-C-6)alkoxy, aminocarbonyl(C1-C6)alkylcarbonylamino, (C C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino, [(Cι-C6)alkyl]2aminocarbonyl(C C6)alkylcarbonylamino, amino(Cι-C6)alkylcarbonylamino, (C C6)alkylamino(Cι- C6)alkylcarbonylamino, [(C -C6)alkyl]2amino(C1-C6)alkylcarbonylamino, ureido(C C6)alkylcarbonylamino, (Cι-C6)alkylureido(CrC6)alkylcarbonylamino, [(C C6)alkyl]2ureido(C1-C6)alkylcarbonylamino, amino(C C6)alkylsulfonylamino, amino(CrC6)alkylcarbonylaminosulfonyl, (Cι-C6)alkylamino(Cr C6)alkylcarbonylaminosulfonyl, [(C1-C6)alkyl]2amino(C1- C6)alkylcarbonylaminosulfonyl, aminosulfonylamino, (Cr
C6)alkylaminosulfonylamino, [(d-CeJalky^aminosulfonylamino, (C2- C9)heterocycloxy, (C2-C9)heteroaryloxy, (C2-C8)heterocycleamino, (C2- C9)heteroarylamino, amino(C C6)alkoxy, (CrC6)alkylamino(Cι-C6)alkoxy, [(C C6)alkyl]2amino(CrC6)alkoxy, amino(C C6)alkylamino, (C C6)alkylcarbonylamino(CrC6)alkylamino,
Figure imgf000052_0001
hydroxy(C C6)alkylamino, (C C6)alkoxy(CrC6)alkylamino, and (C1-C6)alkylsulfonylamino(C1- C6)alkylamino; with the proviso that at least one of R2, R3, R4, and R5 is (d-C^alky!.
2. A compound according to claim 1 , wherein R1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen; W is phenyl; b is 0, 1 or 2 and R6 is selected from a list consisting of halo, (C C6)alkyl, cyano, and (d-C6)alkylcarbonyl.
3. A compound according to claim 1 , wherein R1 is halo; a is 1 or 2; Y is oxygen; Z is oxygen or NH; W is pyridyl; b is 0, 1 or 2 and R6 is selected from a list consisting of halo, (C C6)alkyl, cyano, and (C C6)alkylcarbonyl.
4. A compound according to claim 1 , wherein c is 0, and R7is selected from a list consisting of (d-C6)alkylsulfonylamino, (d-C6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(d-C6)alkylaminocarbonyl, (CrC6)alkylaminocarbonyl, hydroxy(d- C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C8)heterocycloalkoxy, carboxy(C2-C9)heteroarylcarbonyl, ureido(Cι-C6)alkylaminocarbonyl, [(Cr C6)alkyl]2amino(d-C6)alkylaminocarbonyl, (d-C^alkylsulfonylaminocarbony d- C6)alkoxy, aminocarbonyl(CrC6)alkoxy, and carboxy(d-C6)alkoxy.
5. A compound according to claim 1 , wherein c is 1 , and R7 is selected from a list consisting of (CrC6)alkylsulfonylaminocarbonyl(CrC6)alkoxy, (C2- Cg)heteroarylaminocarbonyl(d-C6)alkoxy, and (Cι-C6)alkylsulfonylaminocarbonyl.
6. A compound according to claim 1, wherein R2 and R3 are both methyl groups and R4 and R5are both hydrogen.
7. A compound according to claim 2, wherein R2and R3 are methyl; R4and R5 are hydrogen; R2and R3 are trans; Yand R3 are trans; W is phenyl; c is 0; and R7 is selected from the group consisting of: (C C6)alkylsulfonylamino, (d- C6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(C1-C6)alkylaminocarbonyl, (C C6)alkylaminocarbonyl, hydroxy(C C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C9)heterocycloalkoxy, carboxy(C2-Cg)heteroarylcarbonyl, ureido(C C6)alkylaminocarbonyl, [(Cι-C6)alkyl]2amino(C C6)alkylaminocarbonyl, (Cr C6)alkylsulfonylaminocarbonyl(d-C6)alkoxy, aminocarbonyl(CrC6)alkoxy, and carboxy(C C6)alkoxy.
8. A compound according to claim 3, wherein R2 and R3 are methyl; R4and R5 are hydrogen; R2and R3 are trans; Yand R3 are trans; W is pyridyl; c is 0; and R7 is selected from the group consisting of: (d-C6)alkylsulfonylamino, (d- C6)alkylaminocarbonyl, aminosulfonyl, aminocarbonyl(CrC6)alkylaminocarbonyl, (Cr C6)alkylaminocarbonyl, hydroxy(C1-C6)alkylcarbonylamino, aminocarbonylamino, carboxy(C2-C9)heterocycloalkoxy, carboxy(C2-C9)heteroarylcarbonyl, ureido(Cr C6)alkylaminocarbonyl, [(C C6)alkyl]2amino(CrC6)alkylaminocarbonyl, (d- C6)alkylsulfonylaminocarbonyl(CrC6)alkoxy, aminocarbonyl(CrC6)alkoxy, and carboxy(C C6)alkoxy.
9. A compound according to claim 2, wherein R2 and R are methyl; R4and R5 are hydrogen; R2and R3 are trans; Yand R3 are trans; W is phenyl; c is 1 ; and R7 is selected from the group consisting of: (d-C6)alkylsulfonylaminocarbonyl(Cr C6)alkoxy, (C2-Cg)heteroarylaminocarbonyl(C1-C6)alkoxy, and (C C6)alkylsulfonylaminocarbonyl.
10. A compound according to claim 3, wherein R2 and R3 are methyl; R4and R5 are hydrogen; R2and R3 are trans; Yand R3 are trans; W is pyridyl; c is 1; and R7 is selected from the group consisting of: (d-C^alkylsulfonylaminocarbony^d-C^alkoxy, (C2-C9)heteroarylaminocarbonyl(C C6)alkoxy, and (d-C^alkylsulfonylaminocarbonyl.
11. A compound according to claim 1 , wherein said compound is selected from the group consisting of:
2-(4-Chloro-phenoxy)-1-(4-phenoxy-piperidin-1-yl)-ethanone; 2-(4-Chloro-phenoxy)-1 -[4-(4-fluoro-phenoxy)-piperidin-1 -yl]-ethanone;
5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-benzamide;
(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)- urea;
5-Chloro-2-{(2,4-c/s)-(2,5-^a/?s)-2-[4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1 -yl]-2-oxo-ethoxy}-benzamide;
(2,4-c/s)-(2,5-^ans)-5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetic acid;
N-[(5-Chloro-2-{(2,4-c/s)-(2,5-fraA7s)-2-[4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetyl]-methanesulfonamide; 2-(5-Chloro-2-{2-[(2,4-c/s)-(2,5-?rat?s)-4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-acetamide;
(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)- acetic acid; N-[(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)- acetylj-methanesulfonamide; and
5-Chloro-2-{2-[(2,4-c/'s)-(2,5-fraπs)-4-(4-fluoro-phenoxy)-2,5-dimethyl- piperidin-1-yl]-2-oxo-ethoxy}-benzamide.
12. A pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or during restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; sequelae associated with certain cancers such as multiple myeloma; cancer metastasis, including but not limited to breast cancer; the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1, and IL-6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith);tssue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria) in a mammal, comprising an amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-1 and/or RANTES binding to the receptor CCR1 in a mammal, comprising an amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
14. A method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, Takayasu arthritis, psoriatic arthritis, ankylosing spondylitis, type I diabetes (recent onset), lupus, inflammatory bowel disease, Chrohn's disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, thyroiditis and vasculitis); fibrosis (e.g. pulmonary fibrosis (i.e. idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis), fibrosis associated with end-stage renal disease, fibrosis caused by radiation, tubulointerstitial fibrosis, subepithelial fibrosis, scleroderma (progressive systemic sclerosis), hepatic fibrosis (including that caused by alcoholic or viral hepatitis), primary and secondary biliary cirrhosis); allergic conditions (such as asthma, contact dermatitis and atopic dermatitis); acute and chronic lung inflammation (such as chronic bronchitis, chronic obstructive pulmonary disease, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, immune complex alveolitis); atherosclerosis; vascular inflammation resulting from tissue transplant or duri,πg restenosis (including, but not limited to restenosis following angioplasty and/or stent insertion); other acute and chronic inflammatory conditions (such as synovial inflammation caused by arthroscopy, hyperuremia, or trauma, osteoarthritis, ischemia reperfusion injury, glomerulonephritis, nasal polyosis, enteritis, Behcet's disease, preeclampsia, oral lichen planus, Guillian-Barre syndrome); acute and/or chronic transplant rejection (including xeno-transplantation); HIV infectivity (co-receptor usage); granulomatous diseases (including sarcoidosis, leprosy and tuberculosis); conditions associated with leptin production (such as obesity, cachexia, anorexia, type II diabetes, hyperlipidemia and hypergonadism); Alzheimer's disease; sequelae associated with certain cancers such as multiple myeloma; cancer metastasis, including but not limited to breast cancer; the production of metalloproteinases and cytokines at inflammatory sites (including but not limited to MMP9, TNF, IL-1 , and IL- 6) either directly or indirectly (as a consequence of decreasing cell infiltration) thus providing benefit for diseases or conditions linked to these cytokines (such as joint tissue damage, hyperplasia, pannus formation and bone resorption, hepatic failure, Kawasaki syndrome, myocardial infarction, acute liver failure, septic shock, congestive heart failure, pulmonary emphysema or dyspnea associated therewith); tissue damage caused by inflammation induced by infectious agents (such as viral induced encephalomyelitis or demyelination, viral inflammation of the lung or liver (e.g. caused by influenza or hepatitis), gastrointestinal inflammation (for example, resulting from H. pylori infection), inflammation resulting from: bacterial meningitis, HIV-1 , HIV-2, HIV-3, cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex) fungal meningitis, lyme disease, malaria) in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
15. A method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
PCT/IB2003/002876 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 WO2004009550A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CNA038170922A CN1668592A (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1
JP2004522601A JP2005537279A (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of MIP-1α binding to the receptor CCR1
CA002492651A CA2492651A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
EP03765230A EP1534677A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
MXPA05000380A MXPA05000380A (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1.
AP2005003200A AP2005003200A0 (en) 2002-07-18 2003-07-07 Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.
AU2003242941A AU2003242941A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
BR0312946-2A BR0312946A (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective mip-1alpha inhibitors by binding to their ccr1 receptor
KR10-2005-7000849A KR20050021497A (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
IS7614A IS7614A (en) 2002-07-18 2004-12-23 Piperidine derivatives and their use as a selective inhibitor of MIP-1 alpha binding to its CCR 1 receptor
IL16601004A IL166010A0 (en) 2002-07-18 2004-12-27 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1
TNP2005000014A TNSN05014A1 (en) 2002-07-18 2005-01-18 PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF THE BINDING OF MIP-1 ALPHA TO ITS RECEPTOR CCR1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
US60/397,108 2002-07-18

Publications (1)

Publication Number Publication Date
WO2004009550A1 true WO2004009550A1 (en) 2004-01-29

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002876 WO2004009550A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1

Country Status (24)

Country Link
US (1) US20040063759A1 (en)
EP (1) EP1534677A1 (en)
JP (1) JP2005537279A (en)
KR (1) KR20050021497A (en)
CN (1) CN1668592A (en)
AP (1) AP2005003200A0 (en)
AR (1) AR040583A1 (en)
AU (1) AU2003242941A1 (en)
BR (1) BR0312946A (en)
CA (1) CA2492651A1 (en)
EC (1) ECSP055547A (en)
HN (1) HN2003000222A (en)
IL (1) IL166010A0 (en)
IS (1) IS7614A (en)
MA (1) MA27326A1 (en)
MX (1) MXPA05000380A (en)
OA (1) OA12885A (en)
PA (1) PA8575901A1 (en)
PE (1) PE20040666A1 (en)
TN (1) TNSN05014A1 (en)
TW (1) TW200402416A (en)
UY (1) UY27897A1 (en)
WO (1) WO2004009550A1 (en)
ZA (1) ZA200500067B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066948A1 (en) * 2004-12-20 2006-06-29 Schering Aktiengesellschaft Piperidine derivatives as antagonists of the cc chemokine receptor ccr1 and their use as anti-inflammatory agents
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7449576B1 (en) 2002-06-12 2008-11-11 Chemocentryx, Inc. Substituted piperazines
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7576218B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. 4-phenylpiperdine-pyrazole CCR1 antagonists
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
WO2010077915A1 (en) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
EP2441763A1 (en) 2005-07-26 2012-04-18 Glaxo Group Limited Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
KR20050028036A (en) * 2002-07-18 2005-03-21 화이자 프로덕츠 인크. Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO2001098272A1 (en) * 2000-06-20 2001-12-27 Astrazeneca Ab Novel compounds
EP1179341A1 (en) * 1999-05-18 2002-02-13 Teijin Limited Remedies or preventives for diseases in association with chemokines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (en) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
EP1409477B1 (en) * 2001-07-24 2008-09-17 Richter Gedeon NYRT Piperidine derivatives as nmda receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP1179341A1 (en) * 1999-05-18 2002-02-13 Teijin Limited Remedies or preventives for diseases in association with chemokines
WO2001098272A1 (en) * 2000-06-20 2001-12-27 Astrazeneca Ab Novel compounds

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7449576B1 (en) 2002-06-12 2008-11-11 Chemocentryx, Inc. Substituted piperazines
US8324216B2 (en) 2002-06-12 2012-12-04 Chemocentryx, Inc. Substituted piperazines
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
WO2006066948A1 (en) * 2004-12-20 2006-06-29 Schering Aktiengesellschaft Piperidine derivatives as antagonists of the cc chemokine receptor ccr1 and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
EP2441763A1 (en) 2005-07-26 2012-04-18 Glaxo Group Limited Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US7576218B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. 4-phenylpiperdine-pyrazole CCR1 antagonists
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
WO2010077915A1 (en) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent

Also Published As

Publication number Publication date
CA2492651A1 (en) 2004-01-29
BR0312946A (en) 2005-07-12
AR040583A1 (en) 2005-04-13
CN1668592A (en) 2005-09-14
MA27326A1 (en) 2005-05-02
UY27897A1 (en) 2004-02-27
HN2003000222A (en) 2004-11-23
PE20040666A1 (en) 2004-09-25
AP2005003200A0 (en) 2005-03-31
PA8575901A1 (en) 2004-07-20
KR20050021497A (en) 2005-03-07
IS7614A (en) 2004-12-23
TW200402416A (en) 2004-02-16
TNSN05014A1 (en) 2007-05-14
OA12885A (en) 2006-09-15
ECSP055547A (en) 2005-03-10
JP2005537279A (en) 2005-12-08
AU2003242941A1 (en) 2004-02-09
EP1534677A1 (en) 2005-06-01
ZA200500067B (en) 2005-11-02
MXPA05000380A (en) 2005-03-31
US20040063759A1 (en) 2004-04-01
IL166010A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
US20040063759A1 (en) Novel piperidine derivatives
JP3829136B2 (en) Novel sulfonic acid derivatives
US7098212B2 (en) Piperazine derivatives
EA006079B1 (en) Novel piperazine derivatives
OA12886A (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
US20040092529A1 (en) Methods of using piperazine derivatives
US20020119961A1 (en) Bridged piperazine derivatives
US20040116441A1 (en) Methods of using sulfonic acid derivatives
US20040127465A1 (en) Novel phosphorus-containing derivatives
US20040087797A1 (en) Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003242941

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 166010

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 04129060

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 4166/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: P20041237A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2005/00067

Country of ref document: ZA

Ref document number: 200500067

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000380

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2492651

Country of ref document: CA

Ref document number: P-2005/0033

Country of ref document: YU

Ref document number: 537666

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020057000849

Country of ref document: KR

Ref document number: 200500039

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038170922

Country of ref document: CN

Ref document number: 2004522601

Country of ref document: JP

Ref document number: 20050014

Country of ref document: UZ

Ref document number: 8591/1

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 2003765230

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057000849

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: GE

WWP Wipo information: published in national office

Ref document number: 2003765230

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500060

Country of ref document: PH

WWW Wipo information: withdrawn in national office

Ref document number: 2003765230

Country of ref document: EP